Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)

Historic Gross Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 22.46%.

  • InMed Pharmaceuticals' Gross Margin fell 190000.0% to 22.46% in Q4 2025 from the same period last year, while for Dec 2025 it was 29.73%, marking a year-over-year decrease of 56600.0%. This contributed to the annual value of 34.53% for FY2025, which is 105800.0% up from last year.
  • InMed Pharmaceuticals' Gross Margin amounted to 22.46% in Q4 2025, which was down 190000.0% from 35.99% recorded in Q3 2025.
  • InMed Pharmaceuticals' Gross Margin's 5-year high stood at 67.95% during Q2 2023, with a 5-year trough of 153.07% in Q3 2022.
  • For the 5-year period, InMed Pharmaceuticals' Gross Margin averaged around 23.38%, with its median value being 35.99% (2025).
  • Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Gross Margin was 1554200bps (2023), while the steepest drop was -402600bps (2023).
  • Over the past 5 years, InMed Pharmaceuticals' Gross Margin (Quarter) stood at 42.08% in 2021, then tumbled by -34bps to 27.92% in 2022, then dropped by -6bps to 26.14% in 2023, then skyrocketed by 59bps to 41.46% in 2024, then plummeted by -46bps to 22.46% in 2025.
  • Its Gross Margin was 22.46% in Q4 2025, compared to 35.99% in Q3 2025 and 44.2% in Q2 2025.